TSLA
Tesla
-- 413.897 NVDA
NVIDIA
-- 145.500 PLTR
Palantir
-- 81.930 AAPL
Apple
-- 223.060 TEM
Tempus AI
-- 54.750 
NEWS
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
Monday, 2nd December at 4:05 pm
• Upon closing, the transaction would secure global IP rights for NKGen.
• NKGen and its partners can begin to commercialize troculeucel in Korea, Japan and other markets where natural-killer ("NK") cell therapy is already legal.
• NKGen proposal included up to $18 million in committed funding.
• Closing expected in 1Q 2025.
Monday, 2nd December at 4:05 pm
• Upon closing, the transaction would secure global IP rights for NKGen.
• NKGen and its partners can begin to commercialize troculeucel in Korea, Japan and other markets where natural-killer ("NK") cell therapy is already legal.
• NKGen proposal included up to $18 million in committed funding.
• Closing expected in 1Q 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
7023
Followers
46
Following
76K
Visitors
Follow
Discussing
Trump 2.0 Era: What's the next opportunity in the markets?
▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day